{"createdAt":"8/2/2020, 1:17:36 PM","timestamp":1596388656074,"Company ID number":"113","DMX_ISSUER_NAME":"Chongqing Zhifei Biological Products Co Ltd","DMX_ISSUER_ID":"IID000000002599383","Country of Classification":"CHINA","name":"Chongqing Zhifei Biological Products Co Ltd ","code":"300122","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"重庆智飞生物制品股份有限公司_蒋仁生","group":"board","name":"蒋仁生","title":"董事长,董事","isMale":true,"age":"67","degree":"大专","salary":"67.20万","stockAmount":"8.15亿","description":"蒋仁生,男,1953年出生,汉族,广西灌阳,大专学历,副主任医师,曾任广西壮族自治区灌阳县卫生防疫站副站长、广西壮族自治区计划免疫生物制品副科长,有限公司总经理等职务,现任重庆智飞生物制品股份有限公司董事长、总经理兼党委书记,重庆市江北区人大代表。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_蒋凌峰","group":"board","name":"蒋凌峰","title":"副董事长,董事","isMale":true,"age":"40","degree":"硕士","salary":"75.00万","stockAmount":"8640万","description":"蒋凌峰,男,1980年出生,硕士研究生,中国国籍,无境外居留权。曾任职于广西宾阳县烟草专卖局,近年来先后在智飞龙科马、智飞绿竹任副总经理,现任智飞绿竹副总经理、智飞空港法定代表人及重庆智飞生物制品股份有限公司董事、副总经理。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_秦菲","group":"board","name":"秦菲","title":"董事","isMale":true,"age":"34","degree":"本科","salary":"89.50万","stockAmount":"-","description":"秦菲,男,1986年出生,本科,中国国籍,无境外居留权。2010年加入重庆智飞生物制品股份有限公司,历任重庆智飞生物制品股份有限公司董事会办公室助理、主管、副主任、证券事务代表等职务,现任重庆智飞生物制品股份有限公司董事、董事会秘书。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_李振敬","group":"board","name":"李振敬","title":"董事","isMale":true,"age":"38","degree":"本科","salary":"95.20万","stockAmount":"-","description":"李振敬,男,1982年出生,本科,注册会计师,资产评估师,中国国籍,无境外居留权。曾任职于四川华信(集团)会计师事务所,先后担任项目经理、高级项目经理等职务。2014年加入重庆智飞生物制品股份有限公司,担任风险控制部总监,现任重庆智飞生物制品股份有限公司董事、财务总监。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_杜琳","group":"board","name":"杜琳","title":"董事","isMale":true,"age":"55","degree":"硕士","salary":"86.40万","stockAmount":"-","description":"杜琳,男,1965年出生,中共党员,研究员,硕士研究生导师。1984年,兰州大学细胞生物学专业攻读学士;1988年,兰州大学生物系攻读硕士研究生;1991年毕业分配到兰州生物制品研究所从事科研工作,历任课题负责人、第一研究室副主任、主任职务,参与及组织研发了多个疫苗品种,数个获得国家批准,生产并投放市场,入选甘肃省“555”创新人才工程。2008年10月,加入北京智飞绿竹生物制药有限公司,重庆智飞生物制品股份有限公司副总经理、总经理,现任北京智飞绿竹生物制药有限公司执行董事,并任重庆智飞生物制品股份有限公司董事、研发中心总经理,2015年入选科技北京百名领军人才工程,北京经济技术开发区“新创工程”领军人才,2016年入选北京市高层次创新创业人才支持计划领军人才。","lastUpdated":"2018-08-10"},{"id":"重庆智飞生物制品股份有限公司_杨世龙","group":"board","name":"杨世龙","title":"董事","isMale":true,"age":"56","degree":"硕士","salary":"75.00万","stockAmount":"-","description":"杨世龙,男,1964年出生,研究员、硕士研究生导师、研发带头人。长期从事病毒性疫苗的研究、产业化及管理工作,现任安徽智飞龙科马生物制药有限公司副总经理。曾主持和参与多项疫苗产品的研制工作。","lastUpdated":"2018-08-10"},{"id":"重庆智飞生物制品股份有限公司_刘保奎","group":"board","name":"刘保奎","title":"独立董事","isMale":true,"age":"66","degree":"","salary":"15.00万","stockAmount":"-","description":"刘保奎,男,1954年出生,汉族,研究员,已退休。曾在北京生物制品研究所、北京天坛生物制品股份有限公司、中国生物技术集团公司、中国医药集团总公司从事生物制品、药品的研究、生产、质量管理工作。现为国家药典委员会第十一届委员会委员,《国际生物制品学杂志》编辑委员会编委。","lastUpdated":"2018-08-10"},{"id":"重庆智飞生物制品股份有限公司_章新蓉","group":"board","name":"章新蓉","title":"独立董事","isMale":false,"age":"61","degree":"硕士","salary":"15.00万","stockAmount":"-","description":"章新蓉女士,女,汉族,1959年11月出生,硕士研究生学历,教授,硕士生导师。曾任重庆商学院会计系会计教研室主任,重庆工商大学会计学院副院长、院长。2013年1月至今任重庆工商大学会计学院教师,现任重庆蓝黛动力传动机械股份有限公司独立董事、重庆智飞生物制品股份有限公司独立董事、重庆百货大楼股份有限公司独立董事、重庆莱美药业股份有限公司独立董事。","lastUpdated":"2018-08-10"},{"id":"重庆智飞生物制品股份有限公司_邓纲","group":"board","name":"邓纲","title":"独立董事","isMale":true,"age":"51","degree":"博士","salary":"--","stockAmount":"-","description":"邓纲,男,1969年8月出生,中共党员,法学博士,中国国籍,无境外居留权。西南政法大学教授,博士生导师,兼任中国银行法学研究会常务理事,中国经济法学研究会理事,重庆法学会理事,重庆仲裁委员会仲裁员,中国重庆两江国际仲裁中心仲裁员,鄂尔多斯仲裁委员会仲裁员,重庆学苑律师事务所兼职律师,现任马上消费金融股份有限公司独立董事。","lastUpdated":"2020-06-19"},{"id":"重庆智飞生物制品股份有限公司_吴玉芹","group":"supervisoryCommittee","name":"吴玉芹","title":"监事会主席","isMale":false,"age":"48","degree":"硕士","salary":"60.40万","stockAmount":"-","description":"吴玉芹,女,研究生,中国国籍,无境外居留权。曾担任公司河南市场总经理、市场部经理,现任重庆智飞生物制品股份有限公司市场部总监,职工代表监事。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_李晶","group":"supervisoryCommittee","name":"李晶","title":"监事","isMale":false,"age":"37","degree":"本科","salary":"36.30万","stockAmount":"-","description":"李晶,女,1983年出生,本科,中国国籍,无境外居留权。2011年加入重庆智飞生物制品股份有限公司,曾担任公司内审部经理,现任重庆智飞生物制品股份有限公司风险控制部总监、监事。","lastUpdated":"2018-08-10"},{"id":"重庆智飞生物制品股份有限公司_张郁","group":"supervisoryCommittee","name":"张郁","title":"职工监事","isMale":false,"age":"33","degree":"本科","salary":"52.73万","stockAmount":"1300","description":"张郁,女,本科,中国国籍,无境外居留权。曾担任有限公司人力资源部经理,现任重庆智飞生物制品股份有限公司人力资源部副总监、监事。","lastUpdated":"2018-07-25"},{"id":"重庆智飞生物制品股份有限公司_蒋仁生","group":"manager","name":"蒋仁生","title":"总经理","isMale":true,"age":"67","degree":"大专","salary":"67.20万","stockAmount":"8.15亿","description":"蒋仁生,男,1953年出生,汉族,广西灌阳,大专学历,副主任医师,曾任广西壮族自治区灌阳县卫生防疫站副站长、广西壮族自治区计划免疫生物制品副科长,有限公司总经理等职务,现任重庆智飞生物制品股份有限公司董事长、总经理兼党委书记,重庆市江北区人大代表。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_秦菲","group":"manager","name":"秦菲","title":"董事会秘书","isMale":true,"age":"34","degree":"本科","salary":"89.50万","stockAmount":"-","description":"秦菲,男,1986年出生,本科,中国国籍,无境外居留权。2010年加入重庆智飞生物制品股份有限公司,历任重庆智飞生物制品股份有限公司董事会办公室助理、主管、副主任、证券事务代表等职务,现任重庆智飞生物制品股份有限公司董事、董事会秘书。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_蒋凌峰","group":"manager","name":"蒋凌峰","title":"副总经理","isMale":true,"age":"40","degree":"硕士","salary":"75.00万","stockAmount":"8640万","description":"蒋凌峰,男,1980年出生,硕士研究生,中国国籍,无境外居留权。曾任职于广西宾阳县烟草专卖局,近年来先后在智飞龙科马、智飞绿竹任副总经理,现任智飞绿竹副总经理、智飞空港法定代表人及重庆智飞生物制品股份有限公司董事、副总经理。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_李振敬","group":"manager","name":"李振敬","title":"副总经理,财务总监","isMale":true,"age":"38","degree":"本科","salary":"95.20万","stockAmount":"-","description":"李振敬,男,1982年出生,本科,注册会计师,资产评估师,中国国籍,无境外居留权。曾任职于四川华信(集团)会计师事务所,先后担任项目经理、高级项目经理等职务。2014年加入重庆智飞生物制品股份有限公司,担任风险控制部总监,现任重庆智飞生物制品股份有限公司董事、财务总监。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_张静","group":"manager","name":"张静","title":"副总经理","isMale":false,"age":"51","degree":"硕士","salary":"103.0万","stockAmount":"-","description":"张静女士,女,1969年8月出生,硕士,中国国籍,无境外居留权。2007年加入重庆智飞生物制品股份有限公司,重庆智飞生物制品股份有限公司质量管理部部长、质量管理部总监、监事会主席、总经理助理等职务,现任重庆智飞生物制品股份有限公司副总经理。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_蒋喜生","group":"manager","name":"蒋喜生","title":"副总经理","isMale":true,"age":"60","degree":"本科","salary":"95.20万","stockAmount":"1220万","description":"蒋喜生先生,男,1960年11月出生,本科,经济师、统计师,中国国籍,无境外居留权。2009年加入重庆智飞生物制品股份有限公司,重庆智飞生物制品股份有限公司监事会主席、总经理助理等职务,现任重庆智飞生物制品股份有限公司副总经理。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_孙海天","group":"manager","name":"孙海天","title":"副总经理","isMale":true,"age":"42","degree":"硕士","salary":"95.20万","stockAmount":"-","description":"孙海天先生,男,1978年10月出生,硕士,中国国籍,无境外居留权。2000年取得律师法律资格,中国国籍,无境外居留权。2011年加入重庆智飞生物制品股份有限公司,重庆智飞生物制品股份有限公司法律事务部总监、总经理助理,现任重庆智飞生物制品股份有限公司副总经理。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_谢莉","group":"manager","name":"谢莉","title":"总经理助理","isMale":false,"age":"38","degree":"本科","salary":"82.50万","stockAmount":"-","description":"谢莉女士,女,1982年11月出生,本科,高级人力资源管理师,中国国籍,无境外居留权。2005年加入重庆智飞生物制品股份有限公司,历任有限公司人力资源部经理、股份公司人力资源部总监、监事会主席等职务,现任重庆智飞生物制品股份有限公司总经理助理。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_刘佳","group":"manager","name":"刘佳","title":"总经理助理","isMale":false,"age":"36","degree":"本科","salary":"78.40万","stockAmount":"-","description":"刘佳女士,女,1984年1月出生,本科,中国国籍,无境外居留权。2011年加入重庆智飞生物制品股份有限公司,重庆智飞生物制品股份有限公司办公室副主任、办公室主任、总经办主任,现任重庆智飞生物制品股份有限公司总经理助理。","lastUpdated":"2018-08-14"},{"id":"重庆智飞生物制品股份有限公司_王志军","group":"manager","name":"王志军","title":"总工程师","isMale":true,"age":"54","degree":"本科","salary":"75.00万","stockAmount":"-","description":"王志军,男,1966年10月出生,大学本科,中国国籍,无境外居留权。曾任职于中国生物技术集团公司兰州生物制品研究所,历任菌苗一室主任、生产管理部经理等职务。2009年加入北京智飞绿竹生物制药有限公司,曾任智飞绿竹常务副总经理,现任智飞绿竹副总经理、公司总工程师。","lastUpdated":"2019-04-04"}],"companyName":"重庆智飞生物制品股份有限公司","province":"重庆市","englishName":"Chongqing Zhifei Biological Prdct Co Ltd","industry":"医药生物 — 生物制品Ⅱ","website":"www.zhifeishengwu.com","mainBusiness":"疫苗、生物制品的研发、生产和销售","productsName":["治疗性生物制品","非免疫规划疫苗"],"actualController":"蒋仁生","actualControllerSharePercentage":"50.94%","registeredCapital":"16亿元","employeeAmount":"2972","phone":"86-023-86358226","location":"重庆市江北区金源路7号25层","chineseDescription":"重庆智飞生物制品股份有限公司是一家从事疫苗、生物制品的研发、生产和销售的公司；公司的主要产品为二类苗、治疗性生物制品、二类苗。公司自成立以来，一贯注重研发与技术创新，通过十余年稳步增长的研发投入和持续深入的研发活动，形成了行业较领先的研发技术能力，并为公司可持续发展提供了技术根基。","foundedDate":"1995-07-20","goPublicDate":"2010-09-28","companyHistory":"重庆智飞生物制品股份有限公司(以下简称“公司”或“智飞生物”)，注册资本：160,000万元人民币；注册地址：重庆市江北区金源路7号25-1至25-8；法定代表人：蒋仁生。智飞生物系由原重庆智飞生物制品有限公司（以下简称“有限公司”）以整体变更方式设立的。\n　　2009年9月7日，公司在重庆市工商行政管理局注册登记，统一社会信用代码为91500000203049808L。\n　　2009年8月，根据有限公司股东会决议，有限公司整体变更为股份有限公司，有限公司以截至2009年6月30日经审计净资产374,761,827.09元按1：0.9606的比例折合为股份公司36,000万股股份，其余额14,761,827.09元转入资本公积。其中，蒋仁生持股62%、吴冠江持股29%、蒋凌峰持股6%、余农持股1%、蒋喜生持股1%、陈渝峰持股1%。以上变更经中瑞岳华会计师事务所出具的“中瑞岳华验字[2009]第171号”验资报告确认。根据该验资报告，截至2009年8月16日止，公司已经收到全体股东以净资产投入的股本合计36,000万元。\n　　2010年8月24日，根据中国证券监督管理委员会《关于核准重庆智飞生物制品股份有限公司首次公开发行股票并在创业板上市的批复》（证监许可[2010]1158号）的批复意见，智飞生物获准在创业板公开发行不超过4,000万股新股。\n　　2010年9月13日，智飞生物向社会公开发行人民币普通股票4,000万股（发行价37.98元）。中瑞岳华会计师事务所对本次实收资本变更情况出具了“中瑞岳华验字[2010]第237号”的验资报告予以验证，根据该验资报告，截至2010年9月16日止，智飞生物已收到社会公众股股东新增注册资本（股本）合计人民币40,000,000.00元（肆仟万元整）。社会公众股股东以货币资金实际缴纳出资1,519,200,000.00元（壹拾伍亿壹仟玖佰贰拾万元整）。在扣除全部承销及保荐等费用76,864,000.00元和其他发行费用9,133,052.15元后，实际募集资金净额为1,433,202,947.85元，认缴新增注册资本人民币40,000,000.00元，增加资本公积人民币1,393,202,947.85元。\n　　2014年5月16日，公司股东大会审议通过《2013年年度利润分配预案》，以资本公积金每10股转增10股。公司总股本由400,000,000.00股增至800,000,000.00股。\n　　2016年3月22日，公司股东大会审议通过《重庆智飞生物制品股份有限公司2015年度权益分派预案》，公司以资本公积金向全体股东每10股转增10股。公司总股本由800,000,000.00股增至1,600,000,000.00股。收起▲","shareholders":[{"organizationId":"","holderName":"蒋仁生","totalShare":"8.33亿","sharePercentage":"52.08%"},{"organizationId":"","holderName":"吴冠江","totalShare":"1.16亿","sharePercentage":"7.26%"},{"organizationId":"","holderName":"蒋凌峰","totalShare":"8640.00万","sharePercentage":"5.40%"},{"organizationId":"","holderName":"刘铁鹰","totalShare":"6100.00万","sharePercentage":"3.81%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"5827.99万","sharePercentage":"3.64%"},{"organizationId":"","holderName":"尚信资本管理有限公司-尚信资本-恒兴私募证券投资基金","totalShare":"1812.72万","sharePercentage":"1.13%"},{"organizationId":"","holderName":"云南国际信托有限公司-云南信托-智飞生物2019第二期员工持股集合资金信托计划","totalShare":"1615.00万","sharePercentage":"1.01%"},{"organizationId":"","holderName":"蒋喜生","totalShare":"1320.00万","sharePercentage":"0.83%"},{"organizationId":"","holderName":"国融基金-国泰君安证券-国融天益2号资产管理计划","totalShare":"1021.03万","sharePercentage":"0.64%"},{"organizationId":"","holderName":"国融基金-浦发银行-国融合兴1号资产管理计划","totalShare":"950.00万","sharePercentage":"0.59%"}],"englishDescription":"Chongqing Zhifei Biological Products Co., Ltd. is a China-based company principally engaged in the research, development, production, sale and distribution of vaccine products. The Company's main products include bacterial vaccines for the prevention of meningitis and pneumonia-based bacteria, biological products for the prevision and treatment of tuberculosis, viral vaccines for the prevention of rabies virus, influenza virus and other virus, general drugs and other biological products, among others. The Company is also involved in the agency sale of vaccines. The Company distributes its products in domestic market and to overseas markets, with Central China as its main market.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"125.00","Price to sales (ttm)":"27.23","Price to book (mrq)":"47.51","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"59.66","Lt debt to equity (mrq)":"0.00","Return on investment (ttm)":"42.66","Return on equity (ttm)":"21.59","Income statement":{"Revenue":"10,587.32","Total revenue":"10,587.32","Cost of revenue, total":"6,154.04","Gross profit":"4,433.28","Selling/general/admin. expenses, total":"1,362.27","Research & development":"148.94","Depreciation/amortization":"56.02","Interest exp.(inc.),net-operating, total":"64.43","Unusual expense (income)":"2.25","Other operating expenses, total":"(11.90)","Total operating expense":"7,776.05","Operating income":"2,811.27","Other, net":"(45.89)","Net income before taxes":"2,765.38","Provision for income taxes":"398.94","Net income after taxes":"2,366.44","Net income before extra. items":"2,366.44","Net income":"2,366.44","Income available to com excl extraord":"2,366.44","Income available to com incl extraord":"2,366.44","Diluted net income":"2,366.44","Diluted weighted average shares":"1,600.00","Diluted eps excluding extraord items":"1.48","Dps - common stock primary issue":"0.50","Diluted normalized eps":"1.48","Gain (loss) on sale of assets":"(0.13)"},"Balance sheet":{"Cash":"0.02","Cash & equivalents":"909.70","Cash and short term investments":"909.73","Accounts receivable - trade, net":"4,436.93","Total receivables, net":"4,500.49","Total inventory":"2,484.48","Prepaid expenses":"31.44","Other current assets, total":"240.39","Total current assets":"8,166.52","Property/plant/equipment, total - gross":"2,313.91","Accumulated depreciation, total":"(330.01)","Property/plant/equipment, total - net":"1,983.90","Goodwill, net":"19.28","Intangibles, net":"455.03","Long term investments":"100.62","Other long term assets, total":"217.07","Total assets":"10,942.42","Accounts payable":"2,213.35","Accrued expenses":"293.53","Notes payable/short term debt":"2,393.12","Other current liabilities, total":"172.01","Total current liabilities":"5,072.00","Long term debt":"0.00","Total long term debt":"0.00","Total debt":"2,393.12","Deferred income tax":"24.65","Other liabilities, total":"98.44","Total liabilities":"5,195.08","Common stock, total":"1,600.00","Additional paid-in capital":"207.96","Retained earnings (accumulated deficit)":"3,939.37","Total equity":"5,747.34","Total liabilities & shareholders' equity":"10,942.42","Total common shares outstanding":"1,600.00","Tangible book value per share, common eq":"3.30","Short term investments":"0.78","Treasury stock - common":"(99.51)"},"Cash flow":{"Cash receipts":"8,374.76","Cash payments":"(4,923.52)","Cash taxes paid":"(732.88)","Changes in working capital":"(1,351.37)","Cash from operating activities":"1,366.99","Capital expenditures":"(572.93)","Other investing cash flow items, total":"(49.80)","Cash from investing activities":"(622.73)","Financing cash flow items":"(14.43)","Total cash dividends paid":"(870.68)","Issuance (retirement) of debt, net":"492.31","Cash from financing activities":"(392.80)","Foreign exchange effects":"0.85","Net change in cash":"352.31"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"186.00","52 Week High":"194.21","52 Week Low":"42.42","Pricing date":"","10 Day Average Trading Volume":"26.10","Market Capitalization":"297,600.00","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"303.26","Beta":"1.77","1 Day Price Change":"2.18","13 Week Price Return (Daily)":"134.97","26 Week Price Return (Daily)":"212.13","5 Day Price Return (Daily)":"24.75","52 Week Price Return (Daily)":"308.70","Year To Date Price Return (Daily)":"274.55","Month to Date Price Return (Daily)":"85.72","Price Relative to S&P500 (4 Week)":"74.15","Price Relative to S&P500 (13 Week)":"84.73","Price Relative to S&P500 (26 Week)":"144.48","Price Relative to S&P500 (52 Week)":"177.75","Price Relative to S&P500 (YTD)":"186.47"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"1.48","EPS excl. Extra Items (TTM)":"1.49","EPS Normalized (Annual)":"1.48","Revenue per Share (Annual)":"6.62","Revenue per Share (TTM)":"6.83","Book Value (Per Share Annual)":"3.59","Book Value (Per Share Quarterly)":"3.91","Tangible Book Value (Per Share Annual)":"3.30","Tangible Book Value (Per Share Quarterly)":"3.61","Cash Per Share (Per Share Annual)":"0.57","Cash Per Share (Per Share Quarterly)":"0.71","Cash Flow (Per Share Annual)":"1.54","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.50","Dividends (Per Share TTM)":"0.50","EBITD (Per Share TTM)":"1.83","EPS Basic excl. Extra Items (Annual)":"1.48","EPS Basic excl. Extra Items (TTM)":"1.49","EPS incl. Extra Items (Annual)":"1.48","EPS incl. Extra Items (TTM)":"1.49","Free Cash Flow (Per Share TTM)":"-0.13","Dividend (Per Share 5Y)":"0.24"},"Valuation":{"P/E excl. Extra Items (Annual)":"125.76","P/E excl. Extra Items (TTM)":"125.00","P/E Normalized (Annual)":"125.66","Price to sales (Annual)":"28.11","Price to sales (TTM)":"27.23","Price to Tangible Book (Annual)":"56.44","Price to Tangible Book (Quarterly)":"51.54","Price to Free Cash Flow (Per Share Annual)":"--","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"--","Price to Book (Annual)":"51.78","Price to Book (Quarterly)":"47.51","P/E Basic excl. Extra Items (TTM)":"45.29","P/E excl. Extra Items High (TTM)":"888.73","P/E excl. Extra Items Low (TTM)":"33.57","P/E incl. Extra Items (TTM)":"125.00","Net Debt (Interim)":"2,599.41","Net Debt (Annual)":"1,483.39","Dividend Yield (5Y)":"0.79","Dividend Yield":"0.27","Current Dividend Yield (TTM)":"0.27"},"Financial Strength":{"Free Cash Flow (Annual)":"-76.62","Current Ratio (Annual)":"1.61","Net Interest coverage (Annual)":"44.67","Long Term Debt/Equity (Annual)":"0.00","Payout Ratio (Annual)":"33.81","Quick Ratio (Annual)":"1.12","Total Debt/Total Equity (Annual)":"41.64","Current EV/Free Cash Flow (Annual)":"292.73","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.48","Long Term Debt/Equity (Quarterly)":"0.00","Quick Ratio (Quarterly)":"0.97","Total Debt/Total Equity (Quarterly)":"59.66","Free Cash Flow (TTM)":"-204.04","Net Interest Coverage (TTM)":"29.12","Payout Ratio (TTM)":"33.60"},"Margins":{"Gross Margin (Annual)":"41.87","Gross Margin (TTM)":"40.82","Net Profit Margin % (Annual)":"22.35","Net Profit Margin (TTM)":"21.78","Operating Margin (Annual)":"26.55","Operating Margin (TTM)":"25.81","Pretax Margin (TTM)":"25.57","Pretax Margin (Annual)":"26.12","Operating Margin (5Y)":"28.84","Pretax Margin (5Y)":"28.55","Free Operating Cash Flow/Revenue (5Y)":"-3.48","Free Operating Cash Flow/Revenue (TTM)":"-1.87","Gross Margin (5Y)":"50.56","Net Profit Margin (5Y)":"24.46"},"Management Effectiveness":{"Return on Assets (Annual)":"26.66","Return on Equity (TTM)":"21.59","Return on Average Equity (Annual)":"47.67","Return on Average equity (TTM)":"43.50","Return on Investment (Annual)":"46.65","Return on Investment (TTM)":"42.66","Return on Average Assets (5Y)":"19.36","Return on Average Equity (5Y)":"27.63","Return on Investment (5Y)":"26.82","Asset Turnover (Annual)":"1.19","Asset Turnover (TTM)":"0.99","Inventory Turnover (Annual)":"2.88","Inventory Turnover (TTM)":"2.23","Net Income/Employee (Annual)":"880,207.80","Net Income/Employee (TTM)":"801,055.20","Receivables Turnover (Annual)":"3.30","Receivables Turnover (TTM)":"2.44","Revenue/Employee (Annual)":"3,938,002.00","Revenue/Employee (TTM)":"3,677,113.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"14.87","Revenue Growth Rate (5Y)":"67.59","EPS Growth (Quarterly YoY)":"2.85","EPS Growth (TTM YoY)":"40.56","EPS Growth Rate (5Y)":"74.09","Dividend Growth Rate (3Y)":"268.40","Revenue Growth (TTM YoY)":"63.51","Revenue Growth (Per Share 5Y)":"67.59","Revenue Growth Rate (3Y)":"187.41","EPS Growth Rate (3Y)":"317.46","Book Value Growth Rate (Per Share 5Y)":"18.52","Tangible Book Value Total Equity CAGR (5Y)":"19.58","Capital Spending growth rate 5 year":"15.65","EBITDA CAGR (5Y)":"75.18","EBITDA Interim CAGR (5Y)":"80.71","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"84.22","Net Profit Margin Growth Rate (5Y)":"3.88"},"Income Statement":{"Revenue (Annual)":"10,587.32","Revenue (TTM)":"10,928.38","EBITD (Annual)":"2,976.83","EBITD (TTM)":"2,921.07","Earnings Before Taxes (Annual)":"2,765.38","Earnings Before Taxes (TTM)":"2,794.10","Net Income to Common (Annual)":"2,366.44","Net Income to Common (TTM)":"2,380.74","Earnings Before Taxes Normalized (Annual)":"2,767.63","Net Income Available to Common Normalized (Annual)":"2,368.36","Diluted Normalized EPS excl. Extra Items (TTM)":"1.49"}}}